The sequential gross margin expansion of 510 basis points from 2025Q4 to 2026Q2 appears to reflect easing feedstock costs and operational adjustments, yet operating margin at 10.0% remains below the 2024Q2 level of 9.4% only marginally. The deep negative net margins in 2024Q4 (-80.8%) and 2025Q3 (-56.1%) were driven by large impairments, which distort the true earning power. Investors should focus on gross and operating margins excluding one-time items, as the current net margin of 4.5% likely understates the normalized profitability of the acetyl chain and engineered materials segments.

The sharp swing in ROIC from -5.6% to 1.3% over two quarters is largely attributable to the absence of impairment charges, but the absolute level remains weak relative to the company's historical performance and its cost of capital. ROE at 2.8% in 2026Q2 is similarly depressed, reflecting a thin equity base that has been eroded by cumulative losses. The improvement in asset turnover from 0.10 to 0.13 suggests some operational efficiency gains, but the return on capital is still insufficient to support the current leverage, implying that value creation hinges on sustained margin expansion and debt reduction.

The reduction in DIO from 122 days to 98 days and DSO from 71 to 59 days over the same period suggests that Celanese is managing its working capital more tightly, likely in response to demand softness. DPO has remained relatively stable around 62-67 days, indicating that the company is not stretching supplier payments further. This improvement in CCC is a positive sign for cash generation, but it may also reflect lower inventory levels due to destocking, which could reverse when demand recovers. The asset turnover ratio, though improved to 0.13, remains low, consistent with the capital-intensive nature of the chemical industry.

The D/E ratio of 2.69 is misleadingly high because the equity base has been eroded by cumulative losses and goodwill impairments, not because debt has increased. Interest coverage at 1.26x in 2026Q2 is thin, though it has improved from the negative readings in 2025Q3 and 2024Q4, indicating that operating income is barely sufficient to cover interest expenses. The D/EBITDA ratio of 39.12x in 2026Q2 is extremely elevated, but this is distorted by depressed EBITDA; on a normalized basis, leverage is likely still high but not as extreme. The company's ability to service its debt depends on a sustained recovery in margins and cash flow, which is not yet evident.

The current ratio of 1.23 provides a modest cushion, but the quick ratio of 0.74 suggests that excluding inventory, current assets do not fully cover current liabilities. This is typical for a manufacturer with significant inventory, but it implies that a sudden inventory write-down or demand shock could strain liquidity. Cash balances have increased to $1.4B, which provides some buffer, but the company's high debt load and thin interest coverage mean that liquidity could deteriorate quickly if operating cash flow weakens. The improvement in the current ratio from 1.34 in 2024Q4 to 1.23 in 2026Q2 is modest, and the company remains vulnerable to a prolonged downturn.